E.coli-derived human IkB Beta/NFKBIB recombinant protein (Position: T96-V356). Human NFKBIB shares 79.5% and 76.4% amino acid (aa) sequence identity with mouse and rat NFKBIB, respectively.
Alternative Names:
I kappa B beta, IkappaBbeta, IkB B, IkB beta, IKBB, NF kappa B inhibitor beta, NF kappa BIB, NFKBIB, TR interacting protein 9, TRIP 9, TRIP9
Each vial contains 50% glycerol, 0.9% NaCl, 0.2% Na2HPO4.
Purity:
Immunogen affinity purified.
Form:
Liquid
Target:
NF-kappa-B inhibitor beta
Application Dilute:
Western blot, Optimal dilutions should be determined by end users. Immunohistochemistry (Paraffin-embedded Section), Optimal dilutions should be determined by end users. ELISA, Optimal dilutions should be determined by end users.
* VAT and and shipping costs not included. Errors and price changes excepted